We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01668589
Recruitment Status : Completed
First Posted : August 20, 2012
Results First Posted : September 20, 2016
Last Update Posted : January 30, 2018
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.

Condition or disease
Postmenopausal Osteoporosis

Detailed Description:
The decision to treat patients with denosumab was made independent of and before their enrolment in the study. No study drug was administered as part of the study.

Study Type : Observational
Actual Enrollment : 1501 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium
Actual Study Start Date : November 28, 2011
Primary Completion Date : August 31, 2015
Study Completion Date : August 31, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis
Drug Information available for: Denosumab
U.S. FDA Resources




Primary Outcome Measures :
  1. Percentage of Participants Persistent With Denosumab Injections at 12 Months and 24 Months [ Time Frame: 12 months and 24 months ]

    A participant was considered persistent with denosumab at 12 months if they received at least 1 denosumab injection following the pre-enrolment denosumab injection no later than 6 months + 8 weeks (ie, no greater than 239 days apart).

    A participant was considered persistent with denosumab at 24 months if they received at least 3 denosumab injections following the pre-enrolment denosumab injection, and the length of time between any 2 consecutive denosumab injections did not exceed 6 months + 8 weeks (ie, no greater than 239 days apart).


  2. Percentage of Participants Adherent to Denosumab Injection at 12 Months and 24 Months [ Time Frame: 12 months and 24 months ]

    A participant was considered adherent to denosumab at 12 months if they received at least 1 denosumab injection over the 12-month period following the pre-enrolment denosumab injection, with the time between any 2 consecutive injections being at most 6 months ± 4 weeks (between 155 and 211 days apart).

    A participant was considered adherent to denosumab at 24 months if they received at least 3 denosumab injections over the 24-month period following the pre-enrolment denosumab injection, with the time between any 2 consecutive injections being at most 6 months ± 4 weeks (between 155 and 211 days apart).


  3. Medication Coverage Ratio (MCR) for Denosumab Injection at 12 Months and 24 Months [ Time Frame: From baseline to 12 months and 24 months ]

    MCR at 12 months was defined as the accumulative number of days covered with denosumab treatment during the first 12 months divided by 366 days, expressed as a percentage.

    MCR at 24 months was defined as the accumulative number of days covered with denosumab treatment during the first 24 months divided by 732 days, expressed as a percentage.

    It was assumed that each injection of denosumab treatment provided 6 months of coverage (or 183 days) from the date of injection or until the date of the next injection, whichever comes first. So, a participant who received only 1 injection in the first year would have MCR at 12 months equal to 50%.



Secondary Outcome Measures :
  1. Time to Non-persistence With Denosumab Injection [ Time Frame: 24 months ]
    Time to non-persistence for non-persistent patients was calculated as the time between the date of the first denosumab injection and the date of last denosumab injection received during the period where the patient was still classified as persistent, plus 6 months (183 days). Participants were considered persistent at 24 months if they received at least 4 injections, including the baseline injection, with no more than 6 months + 8 weeks apart between any 2 consecutive injections.

  2. Percentage of Participants Who Received Denosumab Injections Within the Specified Window [ Time Frame: 24 months ]
    The percentage of participants who received 0, 1, 2, or 3 denosumab injections within the specified window (defined by the persistence definition as 6 months + 8 weeks). The number of injections that a participant took during the 2-year period after the first pre-enrolment injection, and that were given within the appropriate window from the previous injection, irrespective of when the previous injection was given. Only the first 3 post-baseline injections are considered.

  3. Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at 24 Months [ Time Frame: Baseline and Month 24 ]
    Bone mineral density was measured using dual energy X-ray absorptiometry (DXA).

  4. Percent Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 24 Months [ Time Frame: Baseline and Month 24 ]
    Bone mineral density was measured using dual energy X-ray absorptiometry (DXA).

  5. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 24 Months [ Time Frame: Baseline and Month 24 ]
    Bone mineral density was measured using dual energy X-ray absorptiometry (DXA).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Postmenopausal women indicated for treatment of osteoporosis at increased risk of fractures according to the approval regional prescribing information, e.g. EU SmPC
Criteria

Inclusion Criteria:

  • Indicated for treatment of osteoporosis in postmenopausal women at increased risk of fractures according to the approved Regional Prescribing Information (eg, EU SmPC in Germany, Austria, Greece and Belgium).
  • Enrolled into the study within 4 weeks of receiving their first injection of Prolia® according to the approved Regional Prescribing Information (eg, EU SmPC in Germany, Austria, Greece and Belgium).
  • Appropriate written informed consent has been obtained (as required per local country regulations).

Exclusion Criteria:

  • Patient is currently enrolled in or has been enrolled within the prior 6 months in a study involving any investigational procedure, device or drug.
  • Contraindicated for treatment with Prolia® according to the approved Regional Prescribing Information (eg, EU SmPC in Germany, Austria, Greece and Belgium).
  • Participation in ongoing or previous denosumab clinical trials.
  • Patient has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the patient to give written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668589


  Show 144 Study Locations
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen

Additional Information:
Publications:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01668589     History of Changes
Other Study ID Numbers: 20110126
First Posted: August 20, 2012    Key Record Dates
Results First Posted: September 20, 2016
Last Update Posted: January 30, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Denosumab
Bone Density Conservation Agents
Physiological Effects of Drugs